Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Penserra Capital Management LLC

Penserra Capital Management LLC grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 39.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,733 shares of the medical equipment provider’s stock after purchasing an additional 1,350 shares during the period. Penserra Capital Management LLC’s holdings in Zimmer Biomet were worth $431,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rovin Capital UT ADV lifted its stake in Zimmer Biomet by 12.0% in the second quarter. Rovin Capital UT ADV now owns 5,405 shares of the medical equipment provider’s stock worth $493,000 after acquiring an additional 579 shares during the last quarter. First Eagle Investment Management LLC increased its position in Zimmer Biomet by 11.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 4,725 shares of the medical equipment provider’s stock valued at $431,000 after acquiring an additional 499 shares during the period. Bryn Mawr Trust Advisors LLC raised its stake in shares of Zimmer Biomet by 9.0% during the second quarter. Bryn Mawr Trust Advisors LLC now owns 63,242 shares of the medical equipment provider’s stock worth $5,768,000 after purchasing an additional 5,229 shares during the last quarter. Savant Capital LLC lifted its stake in shares of Zimmer Biomet by 73.3% in the 2nd quarter. Savant Capital LLC now owns 7,185 shares of the medical equipment provider’s stock worth $655,000 after acquiring an additional 3,039 shares during the period. Finally, Sound Shore Management Inc CT lifted its position in Zimmer Biomet by 16.1% in the second quarter. Sound Shore Management Inc CT now owns 927,258 shares of the medical equipment provider’s stock valued at $84,575,000 after purchasing an additional 128,772 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Up 1.7%

ZBH stock opened at $90.03 on Thursday. The firm’s 50-day simple moving average is $99.17 and its 200 day simple moving average is $97.24. The stock has a market cap of $17.84 billion, a PE ratio of 21.91, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $85.33 and a fifty-two week high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. Zimmer Biomet’s revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were given a $0.24 dividend. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ZBH. Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 target price on the stock. Barclays decreased their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research note on Wednesday, November 5th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. UBS Group cut their price target on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research note on Thursday, November 6th. Finally, Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $109.00.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.